Modeling and Simulation Move Downstream

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-03-15-2016
Volume 2016 eBook
Issue 1
Pages: s22-s25

This article explores two commercial platforms, and touches on a new program underway in the UK.

Today, some of the most advanced computer-based models are being used for early research.  However, the move to continuous processing has stimulated interest in process optimization and control. This article explores two commercial platforms, and touches on a new program underway in the UK.

Read this article

from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.

View other articles in the

2016 Solid Dosage Drug Development and Manufacturing eBook.
Articles in this issue
Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry
Meeting USP Guidelines for Elemental Impurity Analysis with X-ray Fluorescence Spectrometry
Optimizing Tablet Compression
Optimizing Tablet Compression
Excipient-Quality-and-Selection.jpg
Excipient Quality and Selection
Pages-from-PTeBook0316_034-038_continuous_freeman.jpg
Filling the Analysis Gap in the Move to Continuous Processing
Pages-from-PTeBook0316_046-054_Generics_DMFs_Subburaj.jpg
Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances
Pages-from-PTEBook0316_022-025_Modeling.jpg
Modeling and Simulation Move Downstream
Unifying-Excipient-Databases.jpg
Unifying Excipient Databases
Pages-from-PTeBook0316_020-021_Capsugel.jpg
Establishing a New Performance Standard for HPMC Capsules
Recent Videos
Jens Schmidt, associate director MSAT at Lonza
Behind the Headlines episode 8
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Roger Viney, PhD, chief commercial officer for ICE Pharma
Roger Viney, PhD, chief commercial officer for ICE Pharma
Related Content
Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Cytiva Collaborates with Cellular Origins to Deliver Automated Manufacturing for CGTs

Feliza Mirasol
January 22nd 2025
Article

Cytiva will combine its CGT manufacturing technologies with Cellular Origins' robotic manufacturing platform.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Gerresheimer and Bormioli Pharma to Showcase Containment Solutions at Pharmapack

Susan Haigney
January 20th 2025
Article

The two companies will be exhibiting together after Gerresheimer’s December 2024 acquisition of Bormioli.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Lonza and Iconovo Team Up on Intranasal Biologic Candidate

Feliza Mirasol
January 15th 2025
Article

Lonza will work with Iconovo to develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity.

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

PackGene and GC4K Team Up Along with Weill Cornell Medicine for Gene Therapy to Treat Rare Neurological Disease

Feliza Mirasol
January 11th 2025
Article

Through this global alliance, PackGene, Weill Cornell Medicine, and GC4K, an Australian non-profit, intend to deliver a custom-tailored gene therapy solution to treat hereditary spastic paraplegia type 56, a particularly rare neurological disease.